Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

30 Nov 2017

Destiny Pharma - Equity Development Investor Forum - November 2017

Neil Clark, CEO, discusses the Group's activity post-IPO and addresses the firm's plans going forward.

Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Linkedin
Twitter
Youtube

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge